Department of Urology, Mersin City Training and Research Hospital, Korukent Mah. 96015 St. Mersin Integrated Health Campus, Toroslar, Mersin, 33240, Turkey.
Department of Medical Biochemistry, Mersin University Faculty of Medicine, Mersin, Turkey.
BMC Urol. 2024 Sep 28;24(1):210. doi: 10.1186/s12894-024-01592-8.
Bladder cancer continues to be a significant health issue, leading to ongoing research into novel biomarkers and treatment strategies. This study aims to evaluate the potential of serum fibronectin levels and fibronectin gene polymorphisms as biomarkers for predicting the recurrence and treatment response in patients with NMIBC undergoing intravesical BCG therapy.
Between June 2022 and December 2022, data of 73 patients who applied to the Mersin University Urology Clinic due to NMIBC and were followed and treated in our clinic, receiving intravesical BCG treatment, when necessary, as well as 56 individuals without any malignancy, were prospectively examined. Serum fibronectin levels were measured using the enzyme-linked immunosorbent assay method. PCR testing was applied for the fibronectin gene RS10202709 and RS 35,343,655 gene polymorphisms by using Real-Time PCR.
The mean serum fibronectin level in the patient group was 76.794 ± 66.998ng/ml. Simultaneously, it was 50.486 ± 25.156ng/ml in the control group, and these differences in serum fibronectin levels were statistically significant(p = 0.003). Out of the 73 patients included in the study, recurrence of bladder cancer was observed in 53 of them. They were divided into two groups based on the recurrence times: early recurrence and late recurrence. The mean fibronectin level in the early recurrence group was 102 ± 86.1 ng/ml, while it was 44.7 ± 11.8 ng/ml in the late recurrence group. Emphasize the significance of the higher fibronectin levels in the early recurrence group by stating, patients with early recurrence exhibited significantly higher serum fibronectin levels compared to those with late recurrence (p < 0.001), suggesting a potential role for fibronectin as a prognostic biomarker.
The statistically higher concentrations of serum fibronectin levels in patients with bladder cancer observed in our study are a noteworthy finding. These findings suggest that serum fibronectin levels could serve as a valuable prognostic biomarker for early recurrence in NMIBC patients, although their predictive value for BCG treatment response remains limited.
膀胱癌仍是一个重大的健康问题，因此持续在寻找新的生物标志物和治疗策略。本研究旨在评估血清纤维连接蛋白水平和纤维连接蛋白基因多态性作为预测非肌层浸润性膀胱癌（NMIBC）患者接受膀胱内卡介苗（BCG）治疗后复发和治疗反应的潜在生物标志物。
2022 年 6 月至 2022 年 12 月，前瞻性检查了因 NMIBC 就诊于梅斯大学泌尿科诊所并在我们诊所接受随访和治疗（必要时接受膀胱内 BCG 治疗）的 73 例患者和 56 例无恶性肿瘤个体的数据。使用酶联免疫吸附试验法测量血清纤维连接蛋白水平。通过实时聚合酶链反应（PCR）对纤维连接蛋白基因 RS10202709 和 RS35、343、655 基因多态性进行 PCR 检测。
患者组的平均血清纤维连接蛋白水平为 76.794±66.998ng/ml。同时，对照组为 50.486±25.156ng/ml，血清纤维连接蛋白水平差异有统计学意义（p=0.003）。在纳入研究的 73 例患者中，有 53 例发生膀胱癌复发。根据复发次数将其分为早期复发和晚期复发两组。早期复发组的平均纤维连接蛋白水平为 102±86.1ng/ml，晚期复发组为 44.7±11.8ng/ml。强调早期复发组纤维连接蛋白水平较高的重要性，指出与晚期复发组相比，早期复发组患者的血清纤维连接蛋白水平显著升高（p<0.001），提示纤维连接蛋白作为预后生物标志物的潜在作用。
我们的研究观察到膀胱癌患者血清纤维连接蛋白水平升高具有统计学意义，这是一个值得注意的发现。这些发现表明，血清纤维连接蛋白水平可能成为 NMIBC 患者早期复发的有价值的预后生物标志物，尽管其对 BCG 治疗反应的预测价值有限。
